Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Valens in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Valens. This rating has held steady since February 2023, when it changed from a Sell consensus rating.
The Valens Company Inc., engages in the development and manufacturing of cannabinoid based products. The company operates through Cannabis Operations and Analytical Testing segments. The Cannabis Operation segment provides extraction, post processing, and white label manufacturing under the standard processing and standard cultivation license issued by Health Canada. The Analytical Testing segment offers testing services for cannabis products under an analytical testing license provided by Health Canada. The company offers CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, formulation, and white-label product development services. Further, it produces dried cannabis and hemp biomass products. Additionally, the company provides range of products, including tinctures, two-piece caps, soft gels, oral sprays and vape pens, as well as beverages, concentrates, topicals, edibles, injectables, natural health products. It also offers analytical testing services to third party licensed producers in the cannabis space. The company offers a CBD-forward iced tea under the BASECAMP; and THC-forward citrus water under the SUMMIT brand names. The company was formerly known as Valens Groworks Corp. and changed its name to The Valens Company Inc. in June 2020. The Valens Company Inc. is headquartered in Toronto, Canada.
Read More
